AA:EPA

Your body is in a constant tug of war between two fats sitting in nearly every cell membrane: one that largely pushes inflammation forward, and one that helps shut it down. The balance between them shapes how your blood vessels age, how your immune system responds to stress, and how quickly atherosclerotic plaque builds in your arteries.

The AA:EPA ratio (arachidonic acid to eicosapentaenoic acid) puts a number on that balance. A high ratio means the inflammatory side is generally winning. A low ratio means the resolving side has the upper hand. Across studies of coronary artery disease, stroke, heart failure, cancer mortality, and even running injuries, this single ratio repeatedly tracks with risk, often after standard cholesterol and inflammation tests look reassuring.

What the Two Fats Actually Do

AA (arachidonic acid) is an omega-6 fat. When your cells release it from their membranes, enzymes convert it into signaling molecules that, on balance, drive inflammation, blood clotting, and vessel constriction, though some AA-derived signals (such as PGE2 in certain contexts) can also dampen inflammation. EPA (eicosapentaenoic acid) is an omega-3 fat from fatty fish. It competes for the same enzymes and produces signaling molecules that are generally less inflammatory, and in some cases actively help resolve inflammation.

Because the two fats fight for the same metabolic machinery, their ratio matters more than either one alone. A diet rich in seafood pushes EPA up and the ratio down. A diet dominated by processed foods, with little fatty fish, tilts the ratio toward AA. Your genetics, body composition, and inflammatory state also shape where the balance lands.

Heart Disease Risk

The most consistent signal for this ratio is in cardiovascular disease. In a community study of about 3,100 Japanese adults age 40 and older, those with a lower EPA:AA ratio had higher rates of cardiovascular disease over five years, with the effect concentrated in people who also had elevated hs-CRP (high-sensitivity C-reactive protein, a general inflammation marker). The link was strongest for coronary heart disease.

In people without known heart disease, a low EPA:AA ratio is tied to more dangerous plaque features on CT scans. In statin-treated patients with coronary disease, low EPA:AA flags plaques that are more lipid-rich and packed with inflammatory cells, the kind of plaque most likely to rupture. After a heart attack or unstable chest pain, people whose EPA:AA ratio rose substantially over the next three months had roughly half the rate of major cardiovascular events three years later compared with those whose ratio stayed flat.

What this means for you: if your standard lipid panel looks fine but you have a family history of early heart disease, signs of low-grade inflammation, or you simply want to understand whether your fat balance is working for or against your arteries, this ratio adds information that LDL alone cannot.

Stroke and Vascular Disease

In 269 ischemic stroke patients followed for about two years, a higher EPA:AA ratio was independently linked to fewer recurrent vascular events and lower all-cause mortality. In 132 patients with peripheral artery disease who underwent procedures to open leg arteries, low EPA:AA predicted more major limb events and higher death from any cause.

Cancer Mortality

In about 3,100 Japanese community-dwelling adults followed for roughly a decade, people in the lowest EPA:AA quartile had nearly twice the cancer mortality of those in the highest quartile, with the signal strongest for liver cancer. In a small study of lung cancer patients treated with the immunotherapy drug pembrolizumab, those with a higher pretreatment EPA:AA ratio had markedly better overall survival.

Tumor tissue from people with metastatic colorectal cancer carries a higher AA:EPA ratio than non-metastatic tumors, alongside higher levels of inflammatory enzymes. This points to a tissue environment where pro-inflammatory fat signaling may help cancer spread, although the blood ratio is not a cancer screening test on its own.

Kidney and Metabolic Health

In 444 community-dwelling Japanese adults, a low EPA:AA ratio was independently linked to microalbuminuria (early protein leakage from the kidneys, an early sign of vascular damage), even after adjusting for blood pressure, HbA1c, and CRP. In Saudi adults, the EPA:AA ratio outperformed EPA, DHA, and the broader omega-3 index at distinguishing people with elevated blood sugar, with an area under the curve of 0.80.

In 142 overweight Japanese adults with type 2 diabetes admitted for glycemic control, those with a higher EPA:AA ratio at baseline lost more weight during calorie restriction than those with a lower ratio. In women with gestational diabetes, a higher AA:EPA ratio identified those more likely to need pharmacologic therapy and to deliver heavier newborns.

Inflammation, Injury, and Mood

Among 275 recreational runners followed for a year, those with a higher AA:EPA ratio had more running-related injuries, independent of training load. In a community sample of about 2,500 Japanese adults, a higher AA:EPA ratio was tied to a greater likelihood of depressive symptoms, again concentrated in people with elevated inflammation. In colonic tissue from ulcerative colitis patients, AA:EPA rose with the severity of inflammation in the gut wall.

The Atrial Fibrillation Trade-off

Higher EPA is not uniformly protective. In 673 older patients undergoing atrial fibrillation ablation, a higher EPA:AA ratio was associated with more atrial fibrillation recurrence, even though it tracked with fewer major cardiovascular events. In the RESPECT-EPA randomized trial of statin-treated coronary patients with low EPA:AA, high-dose EPA produced a reduction in the primary composite cardiovascular endpoint that fell just short of statistical significance (HR 0.79, p = 0.055), with a significant reduction in the secondary composite of coronary events (HR 0.73), while new-onset atrial fibrillation was significantly higher (3.1% vs 1.6%). The implication: pushing EPA very high may not be the right move for everyone, and the optimal target likely depends on your individual rhythm and vascular risk.

This is not a simple "higher EPA, better health" story. The ratio is a phenotype indicator that captures inflammatory balance, and very high EPA may shift the balance toward fewer atherosclerotic events but more electrical instability in some hearts. Read your number alongside your broader picture rather than chasing an extreme value.

Why One Reading Is Not Enough

Your AA:EPA ratio is a moving target. It shifts with what you ate over the past several weeks, your inflammatory state, and any supplements you take. A single reading captures a moment. The trend captures what your body is actually doing over time.

Get a baseline. If you are changing your diet, adding omega-3 supplements, or starting an intervention aimed at inflammation, retest in three to six months to see whether your number actually moved. Once you have found your stable range, retest at least annually. The combination of a baseline plus a directed retest tells you far more than a single number ever can, and it lets you measure whether what you are doing is working.

When Results Can Be Misleading

Several factors can shift this ratio without reflecting a meaningful change in your biology.

• Recent fish or supplement intake: a large fatty fish meal or a recent omega-3 dose can move EPA temporarily. Standardize when you test relative to your usual diet and supplement timing.
• Acute inflammation: infection, surgery, or recent injury shifts fatty acid metabolism. Wait at least a few weeks after acute illness before drawing a baseline.
• Population context: most published thresholds come from Japanese cohorts with high seafood intake. A "low" ratio in a Western population may not carry the same prognostic weight as the same number in a Japanese cohort, and no universally standardized clinical cutpoint exists.
• Statin therapy: the effect of statins on EPA:AA is statin-specific. Rosuvastatin and pitavastatin do not appear to meaningfully shift the ratio over a 12-week period, while older data suggest simvastatin may actually push the AA:EPA ratio higher over longer follow-up. Note which statin you are on when interpreting the result.

What to Do With an Off-Pattern Result

An unfavorable AA:EPA ratio is most useful when read alongside other markers. If your ratio is high and your hs-CRP is also elevated, the cardiovascular signal from large cohort studies is strongest, and the case for addressing both inflammation and fat balance is stronger. If your ratio is high but your LDL, ApoB, and CRP all look clean, the ratio still warrants attention as an independent risk signal, particularly if you have a family history of early heart disease or stroke.

Pair this test with ApoB or an advanced lipid panel for atherosclerotic risk, hs-CRP for systemic inflammation, and an omega-3 index for a more complete picture of your fat status. If your ratio is very far outside the typical range and you have existing coronary disease, peripheral artery disease, heart failure, or a strong family history, that combination of findings warrants a conversation with a preventive cardiologist or lipidologist who can integrate your fatty acid profile into a broader risk assessment, rather than acting on this one number in isolation.